Covid-19: AstraZeneca vaccine awaiting validation in Europe

The timetable for the arrival of the AstraZeneca vaccine on the European market is becoming clearer.

"The European Medicines Agency has received a request for authorization for a conditional marketing of the vaccine against Covid-19 developed by AstraZeneca and the University of Oxford," she said in a press release published on Tuesday.

A decision could be made on January 29.

EMA receives the application for a conditional marketing authorization of # COVID19 Vaccine AstraZeneca: https://t.co/FVoelj9uvP pic.twitter.com/rpPoVEcNPk

- EU Medicines Agency (@EMA_News) January 12, 2021

The news sounds like an improvement for the British laboratory, industrial partner of the University of Oxford, which has continued to see the effectiveness of its vaccine questioned during the end of 2020. At the end of December, the EMA considered a green light for the AstraZeneca vaccine unlikely at the end of January and wished to obtain “additional scientific information on issues related to the quality, safety and efficacy of the vaccine”.

READ ALSO>

Covid-19: follow our direct

Already issued in the United Kingdom and Argentina, the AstraZeneca vaccine is the first whose efficacy results had been validated by the scientific journal The Lancet.

However, it then experienced a delay in dissemination, linked to unconvincing intermediate results in November.

An additional study was then launched, but the European Medicines Agency does not specify whether the results of this have already reached it.

Why has the European market stalled so much, when the British have been administered the same vaccine since January 4?

According to the EMA, the British regulator had approved the vaccine “in the context of emergency use, separate from a European marketing authorization”.